A Preclinical Therapeutic Study of Minibody 177Lu-DOTAGA-IAB56 Targeting αVβ6 for the Treatment of Pancreatic Cancer
Therapeutic efficacy and dosimetry for a 177-lutetium radiolabeled minibody targeting DLL3 in a preclinical model of small cell lung cancer.
We use cookies to personalize content and ads, and to analyze our traffic and improve our service. Our website uses cookies to remember you and distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site.